Month: June 2025

New York, NY, June 4, 2025 – BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and implied advertising claims made by Bayview Pharmacy Inc. for its compounded semaglutide products.

Novo Nordisk is a global pharmaceutical company specializing in diabetes care, including insulin and related products, as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk is the sole manufacturer of the only FDA-approved semaglutide medicines: Ozempic® and Wegovy®. Bayview, a compounding pharmacy, marketed five concentrations of compounded semaglutide product for sublingual application for blood-sugar control and weight loss on its website.

Novo Nordisk argued that Bayview’s advertising conveyed misleading messages, including that its compounded “semaglutide” sublingual suspensions are Ozempic® and/or is the same as a generic version of Ozempic®. In addition, Novo Nordisk argued that Bayview makes several misleading superiority claims about the bioavailability of its compounded semaglutide sublingual suspension.

During the inquiry, Bayview informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.

In its advertiser statement, Bayview stated it “will comply with NAD’s recommendations” and that it “appreciates NAD’s guidance.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and create fair competition for business.  

Patent litigation shows a strong resurgence in 2024, with over $4.3 billion in damages awarded and a rebound of more than 20% in case filings, driven largely by increases in design patent lawsuits and ANDA litigation

San Jose, CA — June 3, 2025 — Lex Machina®, a LexisNexis® company, today announced the release of its 2025 Patent Litigation Report, providing comprehensive, data-driven insights into the latest trends shaping U.S. patent litigation.

The report analyzes key activity across federal district and appellate courts, as well as the Patent Trial and Appeal Board (PTAB). It is designed to empower legal professionals with unique, data-driven visibility into patterns involving courts, judges, parties, law firms, and attorneys—critical intelligence for developing informed litigation strategies.

Key findings from the report include:

• More than $3 billion in damages were awarded in patent claims in more than 90 cases, a 20% increase over the prior year.
• A rebound of over 20% in patent case filings brought activity back in line with recent historical averages, following a notable drop in This recovery was largely driven by an increase in filings from non-High-Volume Plaintiffs (non-HVPs), who filed over 16% more patent lawsuits in 2024 compared to the average annual rate from 2017 to 2023.
• A 35% increase in design patent lawsuits from 2023, with over 450 cases filed in 2024, demonstrating sustained growth.
• A 20%+ increase in Abbreviated New Drug Application (ANDA) patent litigation filings from 2023, indicating strong This marks the third consecutive annual increase, reaffirming ANDA litigation as a key area of focus for pharmaceutical patent litigators following a period of decline.
• The Eastern District of Texas reclaimed its position as the leading venue for patent Before the 2017 U.S. Supreme Court decision in T.C. Heartland, it consistently led all district courts in patent case volume. While filings shifted between 2018 and 2022 to the Western District of Texas and the District of Delaware, the Eastern District saw a resurgence in 2024 with over 1,000 new patent lawsuits—more than twice as many as the next closest district, the Northern District of Illinois.

“The Lex Machina Patent Litigation Report provides a comprehensive overview of the current landscape in patent litigation,” said Michael J. Flynn, Partner at Morris, Nichols, Arsht & Tunnell LLP. “It serves as an excellent background summary of annual data, offering a valuable starting point for understanding key trends that help inform our clients’ litigation strategies.”

“Recognizing the inherent complexities of patent litigation, in-house litigation teams and law firms stand to benefit significantly from leveraging Legal Analytics to craft their legal strategies,” said Di Rivera, patent legal data expert at Lex Machina and editor of the report. “This edition of the Patent Litigation Report demonstrates how Legal Analytics provides legal teams with comprehensive, actionable intelligence on

the current patent litigation landscape, empowering them to effectively assess case proceedings and advise their clients.”

The Lex Machina Legal Analytics® platform equips litigation professionals to win more cases and attract more business. From precise timing metrics that inform legal budgeting to trend data on top law firms and leading judges, Lex Machina uniquely supplements traditional legal research and experience with customized, data-backed insights. These insights help lawyers identify prospective clients, navigate motion and trial strategies, and negotiate smarter settlements, ultimately giving firms a competitive edge in litigation.

To request a copy of the report, visit https://www.lexisnexis.com/en-us/products/lex-machina/reports.page.

About LexisNexis Legal & Professional

LexisNexis® Legal & Professional provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,800 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

About Lex Machina

Lex Machina fundamentally changes how companies and law firms compete in the business and practice of law. The company provides strategic insights on judges, lawyers, law firms, parties, and other critical information across 22 federal practice areas and a rapidly growing number of state courts. Lex Machina allows law firms and companies to anticipate the behaviors and outcomes that different legal strategies will produce, enabling them to win cases and close business.

Lex Machina was named one of Forbes’ Best Workplaces in the Bay Area in 2024, Winner of the “Media Excellence Award” for Analytics/Big Data 2024, “Great Places to Work” (2023-2024), one of “Legal Tech’s Most Promising Solution Providers” (CIO Review Awards 2022), “Greater Bay Area Top Workplaces 2022” (The San Francisco Chronicle Top Workplaces in the Bay Area 2022), “Legal Tech Company of the Year 2021″ (CIO Review, 2021), “2021 Legal Technology Trailblazer” (National Law Journal Trailblazer Awards, 2021), and Winner of the “Media Excellence” Award for Analytics/Big Data (13th Annual Media Excellence Award, 2021). Based in Silicon Valley, Lex Machina is part of LexisNexis, a leading global provider of legal, regulatory, and business information and analytics. For more information, please visit www.lexmachina.com.

Media Contact Venture PR

lexmachina@venturepr.co

New York, NY, June 3, 2025 — BBB National Programs’ National Advertising Division reviewed a challenge brought by Eli Lilly and Company concerning claims made by Hormone Fitness for its compounded tirzepatide medication.

The inquiry concerned express and implied claims by Hormone Fitness about the benefits, efficacy and safety of its compounded tirzepatide with B12, including assertions of FDA approval, enhanced weight loss, reduced side effects, and superiority over tirzepatide alone.

During the inquiry, Hormone Fitness informed NAD that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.

In its advertiser statement, Hormone Fitness stated, “We are committed to maintaining clear, responsible, and compliant communication in all of our advertising and public materials.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and create fair competition for business.  

New York, NY, June 3, 2025 – BBB National Programs’ National Advertising Division reviewed a challenge brought by Eli Lilly and Company regarding express and implied advertising claims made by Striker Pharmacy, LLC concerning the benefits, efficacy, and safety of its compounded tirzepatide medication.

The challenged health-related claims, regarding the benefits, efficacy, and safety of Striker Pharmacy’s compounded tirzepatide medication, appeared on Striker Pharmacy’s website and Instagram pages.

During the inquiry, Striker Pharmacy informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and create fair competition for business.  

GREENVILLE, S.C., June 03, 2025 – Reliability on the road starts with a tire as tough and driven as the people behind the wheel.

Working fleets are facing more challenges than ever. Growing maintenance costs, challenging working conditions, reducing downtime, and emphasizing driver safety are all factors that must be considered for today’s workforce.

Michelin accelerates the future of commercial driving with the debut of the all-new Agilis® CrossClimate 2, built for relentless reliability and peak performance. From heavy loads to harsh weather, Michelin’s newest all-weather commercial tire keeps business moving with long-lasting performance.

“Michelin recognizes the dedication of the workforce that keeps life in motion, and we’ve created a tire that works just as hard,” said Pierluigi Cumo, VP of B2B Marketing at Michelin North America, Inc. “To deliver every job on schedule, customers need a tire forged with the same strength and resolve as the dedicated individuals whose drive fuels the community they serve. They are the few who drive the many.”

With Michelin’s CurbGard^® technology, the Michelin Agilis^® CrossClimate 2 tire has 70% more sidewall rubber than the Firestone^® Transforce HT2 tire to defend against curb damage[1]. Designed to maximize fleet uptime and control costs, the Michelin Agilis^® CrossClimate 2 tire delivers 35% more mileage than the Firestone^® Transforce HT3 tire.[2] The Michelin Agilis^® CrossClimate 2 tire also provides 35% better snow traction than the Goodyear^® Wrangler Workhorse HT tire.[3] Finally, Michelin’s SipeLock technology features hundreds of biting edges in the tread to help  boost traction for control in challenging conditions, all while backed by the Agilis’ 20% more miles and 60-day satisfaction guarantees[4].

“The Michelin Agilis^® CrossClimate 2 tire is the equivalent of rolling up your sleeves and powering through a job. It doesn’t take breaks, and it doesn’t back down,” said Cumo. “From the job site to the highway, this tire doesn’t flinch. The Agilis^® CrossClimate 2 tire approaches every task with the precision and pride of a master craftsman.”

To meet market demands, Michelin will release the Agilis^® CrossClimate 2 tire in 18 sizes, covering 90%+ of the Commercial Light Truck market, with more sizes planned to be made available in October 2025. For more information on the Michelin Agilis^® CrossClimate 2 tire, please visit our website.

About Michelin North America, Inc.

Michelin is a world-leading manufacturer of life-changing composites and experiences. Pioneering engineered materials for more than 130 years, Michelin is uniquely positioned to make decisive contributions to human progress and to a more sustainable world.

Drawing on its deep know-how in polymer composites, Michelin is constantly innovating to manufacture high-quality tires and components for critical applications in demanding fields as varied as mobility, construction, aeronautics, low-carbon energies and healthcare.

The care placed in its products and deep customer knowledge inspire Michelin to offer the finest experiences. This spans from providing data- and AI-based connected solutions for professional fleets to recommending outstanding restaurants and hotels curated by the MICHELIN Guide.

Headquartered in Greenville, S.C., Michelin North America, Inc. has approximately 23,500 employees and operates 36 production facilities in the United States (michelinman.com) and Canada (michelin.ca).

[1] Based on measurements of the sidewall material thickness between the casing ply and the exterior face of the tire for the Michelin Agilis CrossClimate 2 tire and Firestone® Transforce HT2 tire, all LT225/75R16 size.

[2] Based on an internal treadwear test using tires in size LT225/75R16 on 2023 Ram Promaster vans loaded to 6,800lbs / 3,100kg, Michelin Agilis CrossClimate 2 tire versus the Firestone® Transforce HT3 tire.  Actual on-road results may vary.

[3] Based on third-party snow traction test using ASTM Test Method F1805 on LT225/75R16 tire size, Michelin Agilis CrossClimate 2 tire versus the Goodyear® Wrangler Workhorse HT tire. Actual on-road results may vary. 

[4] Terms & Conditions: * If you’re not 100% satisfied with your new tires, just bring the tires and original sales receipt back to the place where you bought the tires within 60 days of your purchase, and we will gladly exchange them for a new set of tires of equal or lesser value. Certain conditions and limitations apply. See the Michelin Owner’s Manual for complete description and details. **If the Michelin Agilis products do not provide 20% more mileage performance than your current light truck or medium-duty truck tires, we’ll make up the difference of your acquisition price per tire. See the Agilis Family Guarantee page, business.michelinman.com/agilis-family-satisfaction-guarantees, for the full terms and conditions.